UCBClinical Trials•prnewswire•
UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Sentiment:Neutral (60)
Summary
(NYSE:UCB) 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 29, 2025 by prnewswire